Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8WY41

UPID:
NANO1_HUMAN

ALTERNATIVE NAMES:
EC_Rep1a

ALTERNATIVE UPACC:
Q8WY41

BACKGROUND:
Nanos homolog 1, identified by its alternative name EC_Rep1a, is integral to controlling mRNA translation and cell invasion mechanisms. By partnering with PUM2, it selectively represses the translation of target mRNAs. Its role extends to disrupting cell adhesion by interfering with E-cadherin and enhancing MMP14 production, promoting tumor invasion.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Spermatogenic failure 12, where it contributes to significant spermatogenesis abnormalities, Nanos homolog 1 emerges as a promising target for developing treatments for infertility. Moreover, its impact on tumor invasion underscores its therapeutic potential in oncology.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.